Your browser is no longer supported. Please, upgrade your browser.
VYGR [NASD]
Voyager Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.47 Insider Own0.30% Shs Outstand37.78M Perf Week-3.16%
Market Cap111.51M Forward P/E- EPS next Y-2.32 Insider Trans0.00% Shs Float32.70M Perf Month-18.18%
Income-92.80M PEG- EPS next Q-0.53 Inst Own57.10% Short Float7.35% Perf Quarter-0.65%
Sales15.90M P/S7.01 EPS this Y181.00% Inst Trans-6.41% Short Ratio0.43 Perf Half Y-28.17%
Book/sh2.31 P/B1.32 EPS next Y14.00% ROA-41.60% Target Price6.86 Perf Year-63.48%
Cash/sh3.33 P/C0.92 EPS next 5Y- ROE-76.00% 52W Range2.46 - 9.69 Perf YTD-57.20%
Dividend- P/FCF- EPS past 5Y21.60% ROI17.70% 52W High-68.42% Beta1.19
Dividend %- Quick Ratio4.70 Sales past 5Y58.10% Gross Margin- 52W Low24.39% ATR0.24
Employees177 Current Ratio4.70 Sales Q/Q-98.70% Oper. Margin- RSI (14)39.29 Volatility7.61% 7.05%
OptionableYes Debt/Eq0.00 EPS Q/Q-129.30% Profit Margin- Rel Volume0.03 Prev Close3.23
ShortableYes LT Debt/Eq0.00 EarningsNov 02 BMO Payout- Avg Volume5.58M Price3.06
Recom2.80 SMA20-12.77% SMA50-14.10% SMA200-26.90% Volume175,575 Change-5.26%
Oct-07-21Upgrade Robert W. Baird Neutral → Outperform $6 → $9
Feb-26-21Downgrade Robert W. Baird Outperform → Neutral $18 → $6
Feb-03-21Downgrade Wedbush Outperform → Neutral $6
Feb-03-21Downgrade BTIG Research Buy → Neutral
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Nov-10-20Downgrade Wells Fargo Overweight → Equal Weight $10
Nov-10-20Downgrade Raymond James Strong Buy → Outperform $28 → $17
Mar-19-20Initiated The Benchmark Company Buy $18
Feb-06-20Initiated Oppenheimer Outperform
Nov-15-18Upgrade Raymond James Outperform → Strong Buy
Sep-10-18Resumed BTIG Research Buy $32
Sep-10-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18Initiated H.C. Wainwright Buy $30
Mar-12-18Downgrade Wedbush Outperform → Neutral $29
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-02-18Initiated Morgan Stanley Overweight
Nov-28-17Resumed Piper Jaffray Overweight $28
Oct-31-17Initiated Robert W. Baird Outperform $31
Nov-19-21 07:30AM  
Nov-17-21 03:01AM  
Nov-16-21 07:00AM  
Nov-02-21 08:25AM  
07:00AM  
Nov-01-21 03:02PM  
Oct-20-21 08:54AM  
Oct-14-21 11:30AM  
Oct-07-21 12:55PM  
10:23AM  
08:30AM  
Oct-06-21 12:37PM  
12:08PM  
10:23AM  
10:18AM  
08:01AM  
07:32AM  
07:00AM  
Sep-02-21 05:08PM  
Aug-15-21 04:14AM  
Aug-10-21 04:20PM  
Aug-09-21 08:25AM  
07:00AM  
Aug-02-21 03:01PM  
Jun-30-21 07:58AM  
May-19-21 04:01PM  
May-12-21 10:20AM  
07:30AM  
May-11-21 07:30AM  
May-10-21 08:45AM  
07:30AM  
Apr-29-21 10:50AM  
Apr-28-21 12:33PM  
08:00AM  
Apr-27-21 10:10AM  
08:05AM  
Apr-26-21 09:32AM  
08:00AM  
Apr-20-21 10:51AM  
Mar-24-21 10:08AM  
10:00AM  
02:10AM  
Mar-23-21 06:45PM  
06:05PM  
01:00PM  
08:30AM  
Mar-22-21 01:00PM  
08:30AM  
Mar-21-21 08:06PM  
02:20PM  
Mar-19-21 10:29AM  
Mar-18-21 06:14PM  
05:25PM  
10:26AM  
10:00AM  
12:50AM  
Mar-17-21 04:17PM  
02:20PM  
11:00AM  
10:25AM  
Mar-16-21 08:45PM  
11:00AM  
Mar-15-21 12:40PM  
11:00AM  
Mar-14-21 10:54PM  
Mar-12-21 06:00PM  
05:45PM  
02:34PM  
04:05AM  
Mar-11-21 11:45AM  
Mar-10-21 09:56PM  
Mar-09-21 04:40PM  
11:00AM  
10:00AM  
Mar-08-21 09:15PM  
12:30PM  
Mar-07-21 12:44PM  
Mar-06-21 11:30AM  
Mar-05-21 11:55AM  
Mar-03-21 04:12PM  
03:40PM  
01:10AM  
Mar-02-21 12:55PM  
11:00AM  
Mar-01-21 12:20AM  
Feb-28-21 02:41AM  
Feb-27-21 09:00AM  
Feb-26-21 10:04AM  
Feb-25-21 10:14PM  
04:01PM  
02:30PM  
01:19PM  
Feb-24-21 02:04PM  
11:45AM  
Feb-23-21 07:45PM  
11:50AM  
11:20AM  
Feb-22-21 03:16PM  
12:30PM  
12:06PM  
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khwaja OmarSee remarksMay 21Sale4.033,51614,169120,509May 25 04:31 PM
Turenne AndrePresident & CEOFeb 11Sale7.557,97760,226148,375Feb 16 04:11 PM
Dorval AllisonChief Financial OfficerFeb 11Sale7.553,18624,05445,894Feb 16 04:10 PM
Hesslein Robert W.Senior VP & General CounselFeb 11Sale7.553,18624,05449,348Feb 16 04:08 PM
Khwaja OmarSee remarksFeb 11Sale7.553,47526,23653,025Feb 16 04:06 PM
Turenne AndrePresident & CEOJan 12Sale8.6210,44390,019156,352Jan 14 05:59 PM
Dorval AllisonChief Financial OfficerJan 12Sale8.622,94225,36049,080Jan 14 05:57 PM